Biopharmaceutical and molecular biology research team
The biopharmaceutical and molecular biology research team led by Professor Diao Aipo from Tianjin University of Science and Technology has conducted in-depth and systematic research on the biological mechanisms of major diseases, the discovery of new drug targets, and the development of genetically engineered recombinant protein drugs since its establishment in 2009. The team currently has 5 members, among whom Professor Diao Aipo is a specially appointed professor in Tianjin and has been selected for the "New Century Excellent Talents Support Program" of the Ministry of Education and the "Discipline Leading Talent Training Program" of Tianjin University Pharmacy. The current main research directions and achievements include: (1) establishment of recombinant protein expression systems, development of recombinant protein drugs, and pharmacological evaluation. By utilizing microbial fermentation and cell culture techniques, efficient expression of major disease drug target proteins is achieved, which is used for small molecule drug screening, genetic engineering drug preparation, and mechanism of action research. Multiple patents have been applied for related technological achievements. (2) Molecular and cellular biology mechanism research of tumor occurrence. Using lysosomal protein TMEPAI and immune checkpoint protein PD-1/PD-L1 as objects, the mechanism of action in tumor occurrence and development was studied through molecular biology, cell biology, animal models, and other methods. (3) Screening of novel anti-tumor small molecule drugs. Targeting the ubiquitin ligase Nedd4, small molecule compounds that effectively inhibit Nedd4 activity were screened through in vitro models. Meanwhile, a screening system for hTERT expression inhibitors was constructed targeting the telomerase reverse transcriptase (hTERT).
